A/HRC/8/WG.2/TF/2 page 20 76. The task force proposes to explore, during a working session, progress made in realizing Target 17 from the perspective of the right to development criteria in the activities of key partnerships of the private sector (pharmaceutical companies), governments, and multilateral agencies (e.g. WHO, WTO, UNICEF, UNAIDS, UNDP, OHCHR, the World Bank). In this regard, the WHO can be approached, as co-convenor of the High-Level Forum on the Health MDGs, and in light of the special position of its Department of Medicines Policy and Standards, in relation to Target 17, to convene such a working session. The task force considers that these issues would be best addressed through two separate sessions: one dealing with procurement and pricing issues and involving primarily public-private partnerships, with relevant multilateral initiatives,19 and the second devoted to trade-related aspects of intellectual property protection under the TRIPS agreement of WTO and bilateral and regional free trade agreements, involving relevant institutions.20 These sessions would also provide an opportunity for the Special Rapporteur to present his guidelines to the stakeholders. 2. MDG 8, Targets 13 and 15: Debt relief and sustainability 77. At its first session, the task force considered a heavy debt burden as a major obstacle for poor developing countries in achieving the MDGs and in meeting their obligations under the International Covenant on Economic, Social and Cultural Rights.21 It considered the matter further at its second session deeming it necessary to define debt sustainability within a State context with a view to attaining a level of debt that allows countries to achieve the MDGs and avoid an increase in debt ratios by 2015 and agreed that poverty reduction and promotion and protection of human rights should be key considerations in finding solutions for debt sustainability.22 Finally, it considered that a State’s obligation to service national debt had to Montréal, the following institutions organized a workshop on the evaluation from the right to development perspective of Target 17 on 20 November 2007 at the: Association pour la santé publique du Québec, Initiative luso-francophone sur l’accès au médicament et la protection du citoyen, Program on Human Rights in Development of the Harvard School of Public Health, Canadian Institutes of Health Research, the Réseau de recherche en santé des populations du Québec, and the Groupe d’étude sur l’interdisciplinarité et les représentations sociales of the Université du Quebec à Montréal. 19 This includes the Interagency Pharmaceutical Coordination Group, the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Bill and Melinda Gates Foundation, the GAVI Alliance and the Clinton Foundation’s HIV/AIDS Initiative. 20 Institutions include WTO, the World Health Organization (WHO), UNDP, UNCTAD and the World Intellectual Property Organization (WIPO). 21 E/CN.4/2005/WG.18/2, para. 48. 22 E/CN.4/2005/WG.18/TF/3, paras. 62.